<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287989</url>
  </required_header>
  <id_info>
    <org_study_id>J0432</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0432</secondary_id>
    <secondary_id>JHOC-WIRB-20041142</secondary_id>
    <secondary_id>CDR0000455116</secondary_id>
    <secondary_id>20-04-11-42</secondary_id>
    <nct_id>NCT00287989</nct_id>
  </id_info>
  <brief_title>Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Randomized Phase II Trial Comparing Two Doses of Pulsed Erlotinib Prechemotherapy (PEP-C) in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work
      in different ways to stop the growth of tumor cells, either by killing the cells or by
      stopping them from dividing. Giving erlotinib together with paclitaxel and carboplatin may
      kill more tumor cells.

      PURPOSE: This randomized phase II trial is studying two different doses of erlotinib when
      given together with paclitaxel and carboplatin to compare how well they work in treating
      patients with stage III, stage IV, or recurrent non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the major objective response (complete and partial response) rates in patients
           with stage IIIB or IV or recurrent non-small cell lung cancer treated with high- versus
           low-dose erlotinib hydrochloride combined with paclitaxel and carboplatin.

        -  Compare the duration of response, time to progression, and survival of patients treated
           with these regimens.

        -  Characterize and compare the toxicities of these regimens.

        -  Determine the recommended phase III dose of erlotinib hydrochloride.

      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified
      according to gender. Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive oral high-dose erlotinib hydrochloride on days 1 and 2. Patients
           also receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on
           day 3.

        -  Arm II: Patients receive oral low-dose erlotinib hydrochloride, paclitaxel, and
           carboplatin as in arm I.

      In both arms, treatment repeats every 21 days for 6 courses in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed periodically.

      PROJECTED ACCRUAL: A total of 58 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>after 6 cycles of chemotherapy</time_frame>
    <description>Percentage of patients who experienced complete or partial response as defined by RECIST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>after cycle 6 of chemotherapy</time_frame>
    <description>Median number of months until disease progression</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>150 PRE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150mg on days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200 mg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1,500 PRE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 1500mg on Days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200mg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1,500 POST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC6, Paclitaxel 200 mg/m2 followed by Erlotinib 1500mg days 2 and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>1,500 POST</arm_group_label>
    <arm_group_label>1,500 PRE</arm_group_label>
    <arm_group_label>150 PRE</arm_group_label>
    <other_name>Carboplatin AUC6</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>150mg</description>
    <arm_group_label>150 PRE</arm_group_label>
    <other_name>Erlotinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>200mg/m2</description>
    <arm_group_label>1,500 POST</arm_group_label>
    <arm_group_label>1,500 PRE</arm_group_label>
    <arm_group_label>150 PRE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>1500mg</description>
    <arm_group_label>1,500 POST</arm_group_label>
    <arm_group_label>1,500 PRE</arm_group_label>
    <other_name>Erlotinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Pathologically confirmed non-small cell lung cancer

               -  Stage IIIB or IV or recurrent disease

          -  Measurable or evaluable indicator lesions

          -  Must have smoked ≥ 100 cigarettes in his/her lifetime

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 70-100%

          -  WBC ≥ 4,000/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min

          -  Bilirubin ≤ 1.0 mg/dL

          -  AST ≤ 2.5 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 2.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for ≥ 1 week after
             completion of study treatment

          -  No gastrointestinal tract disease or inability to take oral medication

          -  No prior malignancy within the past 2 years except nonmelanoma skin cancer or
             carcinoma in situ of the cervix

          -  No other active medical problems, including severe infection, unstable angina, or
             myocardial infarction within the past 6 months

          -  No poorly controlled hypertension or severe malnutrition

          -  No New York Heart Association class III or IV congestive heart failure or serious
             cardiac arrhythmia requiring medication except chronic atrial arrhythmia (i.e., atrial
             fibrillation or paroxysmal supraventricular tachycardia)

        PRIOR CONCURRENT THERAPY:

          -  At least 3 weeks since prior radiotherapy to major bone marrow-containing sites

          -  No prior chemotherapy for advanced non-small cell lung cancer

          -  No prior agents directed at the epidermal growth factor receptor (EGFR)/HER axis
             (e.g., gefitinib, cetuximab, or trastuzumab [Herceptin®])

          -  No prior surgical procedure resulting in abnormal absorption of oral medications

          -  No concurrent surgical resection, palliative radiotherapy, or hormonal therapy

          -  No other concurrent anticancer therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles M. Rudin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Riely GJ, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, Senturk E, Azzoli CG, Brahmer JR, Sirotnak FM, Seshan VE, Fogle M, Ginsberg M, Miller VA, Rudin CM. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jan 10;27(2):264-70. doi: 10.1200/JCO.2008.17.4656. Epub 2008 Dec 1.</citation>
    <PMID>19047285</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 6, 2006</study_first_submitted>
  <study_first_submitted_qc>February 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2006</study_first_posted>
  <results_first_submitted>March 20, 2017</results_first_submitted>
  <results_first_submitted_qc>November 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 6, 2018</results_first_posted>
  <last_update_submitted>November 12, 2018</last_update_submitted>
  <last_update_submitted_qc>November 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>150 PRE</title>
          <description>Erlotinib 150mg on days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200 mg/m2</description>
        </group>
        <group group_id="P2">
          <title>1,500 PRE</title>
          <description>Erlotinib 1500mg on Days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200mg/m2</description>
        </group>
        <group group_id="P3">
          <title>1,500 POST</title>
          <description>Carboplatin AUC6, Paclitaxel 200 mg/m2 followed by Erlotinib 1500mg days 2 and 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>150 PRE</title>
          <description>Erlotinib 150mg on days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200 mg/m2</description>
        </group>
        <group group_id="B2">
          <title>1,500 PRE</title>
          <description>Erlotinib 1500mg on Days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200mg/m2</description>
        </group>
        <group group_id="B3">
          <title>1,500 POST</title>
          <description>Carboplatin AUC6, Paclitaxel 200 mg/m2 followed by Erlotinib 1500mg days 2 and 3.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="51" upper_limit="81"/>
                    <measurement group_id="B2" value="62" lower_limit="42" upper_limit="78"/>
                    <measurement group_id="B3" value="62" lower_limit="43" upper_limit="81"/>
                    <measurement group_id="B4" value="64" lower_limit="42" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate</title>
        <description>Percentage of patients who experienced complete or partial response as defined by RECIST</description>
        <time_frame>after 6 cycles of chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150 PRE</title>
            <description>Erlotinib 150mg on days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200 mg/m2</description>
          </group>
          <group group_id="O2">
            <title>1,500 PRE</title>
            <description>Erlotinib 1500mg on Days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200mg/m2</description>
          </group>
          <group group_id="O3">
            <title>1,500 POST</title>
            <description>Carboplatin AUC6, Paclitaxel 200 mg/m2 followed by Erlotinib 1500mg days 2 and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Percentage of patients who experienced complete or partial response as defined by RECIST</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="6" upper_limit="37"/>
                    <measurement group_id="O2" value="34" lower_limit="18" upper_limit="54"/>
                    <measurement group_id="O3" value="28" lower_limit="13" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Median number of months until disease progression</description>
        <time_frame>after cycle 6 of chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150 PRE</title>
            <description>Erlotinib 150mg on days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200 mg/m2</description>
          </group>
          <group group_id="O2">
            <title>1,500 PRE</title>
            <description>Erlotinib 1500mg on Days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200mg/m2</description>
          </group>
          <group group_id="O3">
            <title>1,500 POST</title>
            <description>Carboplatin AUC6, Paclitaxel 200 mg/m2 followed by Erlotinib 1500mg days 2 and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Median number of months until disease progression</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O3" value="5" lower_limit="3" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>150 PRE</title>
          <description>Erlotinib 150mg on days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200 mg/m2</description>
        </group>
        <group group_id="E2">
          <title>1,500 PRE</title>
          <description>Erlotinib 1500mg on Days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200mg/m2</description>
        </group>
        <group group_id="E3">
          <title>1,500 POST</title>
          <description>Carboplatin AUC6, Paclitaxel 200 mg/m2 followed by Erlotinib 1500mg days 2 and 3.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The design of the study was change during the course of this research.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Charles M. Rudin, MD, PhD.</name_or_title>
      <organization>MSKCC</organization>
      <phone>646-888-4527</phone>
      <email>rudinc@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

